

## Tozinameran

S

### Lower extremity deep venous thrombosis and vaccine failure: 8 case reports

In an observational, retrospective, monocentric study of 697 patients vaccinated between 14 April 2021 and 14 May 2021 at a centre in Italy, 8 patients including a 35-year-old woman and 7 patients [sexes *not stated*] aged 38–62 years were described, who developed lower extremity deep venous thrombosis or experienced vaccine failure following vaccination with tozinameran against COVID-19 [*routes, dosages and outcome of ADR not stated*].

The 35-year-old woman (from table 4), who had HIV (diagnosed in 2013) and osteopenia, had been receiving drospirenone, ethinylestradiol, cholecalciferol and antiretroviral therapy (ART) with abacavir/dolutegravir/lamivudine. She received tozinameran [BNT162b2 COVID-19 mRNA vaccine] injection and developed a serious adverse event of lower extremity deep venous thrombosis after ~24 h of vaccination secondary to tozinameran. The 7 patients (from table 5), who had HIV, had been receiving unspecified ART. Three of them had hypertension or diabetes. They received tozinameran [BNT162b2 COVID-19 mRNA vaccine] injection, which was scheduled for two doses, 21 days apart. After 3 months, a non-protective titre, indicating vaccine failure, was observed. They had <50 AU/mL of IgG antibodies against receptor binding domain titre for severe acute respiratory syndrome-related coronavirus.

Milano E, et al. Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: A monocentric study in Bari, Italy. *Journal of Medical Virology* 94: 2230-2236, No. 5, May 2022. Available from: URL: <https://onlinelibrary.wiley.com/doi/10.1002/jmv.27629> 803663066